Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | ALPL | P05186 | 1/20 | 0.30 |
| ▸ | ALPI | P09923 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Valine SCHEMBL20640368 | 0.87 | L3MBTL1 (0.33) | NPC1PKM | |
| SCHEMBL13724043 | 0.86 | TP53 (0.34) | TP53MAPTSMN1; SMN2ALPLALPI | |
| SCHEMBL13724157 | 0.80 | TP53 (0.33) | TP53MAPTSMN1; SMN2 | |
| SCHEMBL21138064 | 0.80 | MAPT (0.40) | TP53MAPTSMN1; SMN2PKM | |
| SCHEMBL13723919 | 0.80 | TP53 (0.35) | TP53MAPTSMN1; SMN2 | |
| SCHEMBL13723117 | 0.79 | DYRK1A (0.41) | TP53MAPTSMN1; SMN2PKM | |
| SCHEMBL21562695 | 0.78 | MAPT (0.34) | TP53MAPTSMN1; SMN2PKM | |
| SCHEMBL13731320 | 0.77 | — | — | |
| SCHEMBL23415199 | 0.76 | MEN1 (0.34) | TP53MAPTSMN1; SMN2NPC1PKM | |
| SCHEMBL21550396 | 0.75 | TP53 (0.33) | TP53MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112088160-B | 1-imidazothiadiazolo-2H-pyrrol-5-one derivatives | UCB生物制药有限责任公司 | 2023-07-04 | — | — | CN | disclosed |
| EP-3790885-B1 | 1-IMIDAZOTHIADIAZOLO-2H-PYRROL-5-ONE DERIVATIVES | UCB Biopharma SRL (BE) | 2023-04-19 | — | — | EP | disclosed |
| US-11286266-B2 | 1-imidazothiadiazolo-2H-pyrrol-5-one derivatives | UCB Biopharma SRL | 2022-03-29 | — | — | US | disclosed |
| US-11155565-B2 | 2-oxo-1,3-oxazolidinyl imidazothiadiazole derivatives | UCB Biopharma SRL | 2021-10-26 | — | — | US | disclosed |
| US-11155565-B2 | 2-oxo-1,3-oxazolidinyl imidazothiadiazole derivatives | UCB Biopharma SRL | 2021-10-26 | — | — | US | disclosed |
| EP-3652183-B1 | 2-OXO-1,3-OXAZOLIDINYL IMIDAZOTHIADIAZOLE DERIVATIVES | UCB Biopharma SRL (BE) | 2021-09-08 | — | — | EP | disclosed |
| EP-3652183-B1 | 2-OXO-1,3-OXAZOLIDINYL IMIDAZOTHIADIAZOLE DERIVATIVES | UCB Biopharma SRL (BE) | 2021-09-08 | — | — | EP | disclosed |
| US-20210107922-A1 | 1-IMIDAZOTHIADIAZOLO-2H-PYRROL-5-ONE DERIVATIVES | UCB BIOPHARMA SRL (SOCIETE A RESPONSABILITE LIMITEE) (BE) | 2021-04-15 | — | — | US | disclosed |
| US-20200231599-A1 | 2-OXO-1,3-OXAZOLIDINYL IMIDAZOTHIADIAZOLE DERIVATIVES | UCB BIOPHARMA SPRL (BE) | 2020-07-23 | — | — | US | disclosed |
| US-20200231599-A1 | 2-OXO-1,3-OXAZOLIDINYL IMIDAZOTHIADIAZOLE DERIVATIVES | UCB BIOPHARMA SPRL (BE) | 2020-07-23 | — | — | US | disclosed |
| EP-2699581-B1 | 2-OXO-1-IMIDAZOLIDINYL IMIDAZOTHIADIAZOLE DERIVATIVES | UCB BIOPHARMA SPRL (BE) | 2015-11-25 | — | — | EP | disclosed |
| US-8957218-B2 | 2-oxo-1-imidazolidinyl imidazothiadiazole derivatives | UCB PHARMA S.A. (BE) | 2015-02-17 | — | — | US | disclosed |
| US-8957218-B2 | 2-oxo-1-imidazolidinyl imidazothiadiazole derivatives | UCB PHARMA S.A. (BE) | 2015-02-17 | — | — | US | disclosed |
| US-8957218-B2 | 2-oxo-1-imidazolidinyl imidazothiadiazole derivatives | UCB PHARMA S.A. (BE) | 2015-02-17 | — | — | US | disclosed |
| US-20140148489-A1 | 2-Oxo-1-Imidazolidinyl Imidazothiadiazole Derivatives | UCB PHARMA, S.A. (BE) | 2014-05-29 | — | — | US | disclosed |
| US-20140148489-A1 | 2-Oxo-1-Imidazolidinyl Imidazothiadiazole Derivatives | UCB PHARMA, S.A. (BE) | 2014-05-29 | — | — | US | disclosed |
| US-20140148489-A1 | 2-Oxo-1-Imidazolidinyl Imidazothiadiazole Derivatives | UCB PHARMA, S.A. (BE) | 2014-05-29 | — | — | US | disclosed |
| EP-2699581-A1 | 2-OXO-1-IMIDAZOLIDINYL IMIDAZOTHIADIAZOLE DERIVATIVES | UCB Pharma, S.A. (BE) | 2014-02-26 | — | — | EP | disclosed |
| WO-2012143116-A1 | 4-OXO-1-IMIDAZOLIDINYL IMIDAZOTHIADIAZOLE DERIVATIVES | UCB PHARMA, S.A. (BE) | 2012-10-26 | — | — | WO | disclosed |
| WO-2012143117-A1 | 2-OXO-1-IMIDAZOLIDINYL IMIDAZOTHIADIAZOLE DERIVATIVES | UCB PHARMA, S.A. (BE) | 2012-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11155565-B2 | 2-oxo-1,3-oxazolidinyl imidazothiadiazole derivatives | CYP3A43, CYP3A4, CYP3A7 | TP53 3658/4885MAPT 2052/4885SMN1; SMN2 2340/4885 |
| US-20140148489-A1 | 2-Oxo-1-Imidazolidinyl Imidazothiadiazole Derivatives | CYP3A4, CYP3A43, CYP3A7 | TP53 2654/4885MAPT 956/4885SMN1; SMN2 2264/4885 |
| US-11286266-B2 | 1-imidazothiadiazolo-2H-pyrrol-5-one derivatives | TPMT, THPO, PKD1 | TP53 2196/4885MAPT 570/4885SMN1; SMN2 2243/4885 |
| US-20200231599-A1 | 2-OXO-1,3-OXAZOLIDINYL IMIDAZOTHIADIAZOLE DERIVATIVES | CYP3A43, CYP3A4, CYP3A7 | TP53 3658/4885MAPT 2052/4885SMN1; SMN2 2340/4885 |
| US-20210107922-A1 | 1-IMIDAZOTHIADIAZOLO-2H-PYRROL-5-ONE DERIVATIVES | TPMT, THPO, PKD1 | TP53 2196/4885MAPT 570/4885SMN1; SMN2 2243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.